Today: 7 February 2026
Subscribe
Browse Category

Pharma News News 11 November 2025 - 26 November 2025

Sumitomo Pharma (TSE:4506) Jumps Over 5% Today – Stock Price on 26 November 2025, Earnings Upgrade and Outlook

Sumitomo Pharma (TSE:4506) Jumps Over 5% Today – Stock Price on 26 November 2025, Earnings Upgrade and Outlook

TOKYO — 26 November 2025 — Sumitomo Pharma Co., Ltd. (TSE:4506), one of Japan’s mid‑to‑large cap pharmaceutical names, extended its remarkable 2025 rally today, with the share price surging again as investors continued to digest a major earnings upgrade and strong North American growth. Sumitomo Pharma stock price today (26 November 2025) On the Tokyo Stock Exchange Prime Market, Sumitomo Pharma closed up 5.6% at ¥2,633 on Wednesday, 26 November 2025. Intraday, the stock: Real‑time data from Japanese platforms around the midday break showed the stock near ¥2,630.5, up 5.5%, underpinning the strength of the move and a busy retail
26 November 2025
····
Bayer Aktie (BAYN) Soars Over 10% on Stroke Drug Breakthrough – All Key News for 24 November 2025

Bayer Aktie (BAYN) Soars Over 10% on Stroke Drug Breakthrough – All Key News for 24 November 2025

Bayer’s share price is having its strongest single session in a long time. On Monday, 24 November 2025, the Bayer Aktie (BAYN) on Xetra jumped roughly 9–11% to trade around €30–31, briefly touching a new year high near €31 and closing a little above €30.5 according to German market data.finanzen.net+1 The rally was powerful enough for Bayer to top the STOXX 600 leaderboard, with Reuters reporting a gain of about 9.3% by the European close, making the stock the strongest performer in the index.Reuters The driver: a Phase III triumph for the company’s experimental stroke drug asundexian, plus fresh headlines
24 November 2025
···
Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck Stock Jumps on Wells Fargo Upgrade and New Keytruda Wins – MRK Today, November 24, 2025

Merck & Co., Inc. (NYSE: MRK) is suddenly back in the market’s spotlight. On Monday, 24 November 2025, Merck’s share price surged to around $102, up roughly 4–4.5% on the day, after a bullish analyst upgrade collided with fresh regulatory and pipeline news around its flagship cancer drug Keytruda. TradingView+2Yahoo Finance+2 At the same time, Merck released new hematology pipeline data heading into the ASH 2025 meeting, secured another FDA green light in bladder cancer, and drew attention for increased institutional buying — making MRK one of the most talked‑about big‑pharma stocks of the session. MarketBeat+3Merck.com+3Stock Titan+3 Here’s a full
24 November 2025
····
Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly (LLY) Stock Today, November 24, 2025: Trillion‑Dollar Milestone, $1,300 Price Target and New Weight‑Loss Shot Data

Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks on Wall Street today as it trades just below the historic $1 trillion valuation it briefly reached on Friday, while fresh analyst upgrades, new obesity‑drug data and a major setback for rival Novo Nordisk’s Alzheimer’s program dominate the news cycle. Reuters+1 Key takeaways for LLY on 24 November 2025 Eli Lilly stock price today: still trading like a tech high‑flyer As of around late morning U.S. time on Monday, November 24, 2025, Eli Lilly shares are trading near $1,069.56, up about $9.86 on the session, a
24 November 2025
···
AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

Published: November 23, 2025 – Ticker: NYSE: ABBVThis article is for informational purposes only and is not financial advice. Key takeaways AbbVie stock price today: still near the top of its range U.S. markets are closed today (Sunday), so the latest full trading session for AbbVie stock (ABBV) was Friday, November 21, 2025. AbbVie: The stock is trading close to its 52‑week range of $164.39 to $244.81, leaving shares only a few percentage points below their recent high. Investing Performance context: In short, AbbVie enters this week with strong momentum and a share price that already reflects a lot of
23 November 2025
····
GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc (LON:GSK, NYSE:GSK) finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop. Key takeaways for GSK shareholders today GSK share price today: how LON:GSK traded on 20 November 2025 Based on end‑of‑day data from Hargreaves Lansdown, GSK closed the London session at around 1,776p, a gain of about 0.23% versus Wednesday’s close of 1,772.5p. The stock opened at 1,778p, touched an intraday high near 1,790.3p, and briefly dipped to about 1,772p before settling in
20 November 2025
···
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1 Key terms of
17 November 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
14 November 2025
······
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Key points at a glance Deal terms: a rich premium for a single late‑stage asset Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price
14 November 2025
···
Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

What’s new today (Nov. 12) Canaccord bumps target to $107. Before the open, Canaccord Genuity’s Edward Nash inched his VKTX target up by $1 to $107 and kept a Buy rating, framing Viking as a high‑quality obesity asset. The update follows Canaccord’s October initiation and comes as investors digest Stifel conference commentary and the latest clinical posters. StreetInsider.com+1 Stock check. VKTX traded around the low‑$40s today as conference headlines and sell‑side notes hit the tape. (See the live chart above; for a public quote page, Reuters lists VKTX real‑time pricing and ranges.) Reuters Fund‑flow tidbits. 13F‑driven headlines this morning highlighted
12 November 2025
···
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom What’s happening today (Nov. 11) Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025
11 November 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and Merck together contributed an estimated ~36 points to the index’s ~386‑point climb at that time. MarketWatch In a separate Data Talk update, MRK was up for a sixth straight session, putting it on pace for its longest winning streak since August and tracking toward its highest close since Oct. 1—contingent on late‑day trading. Morningstar Regulatory update: FDA okays Promega’s OncoMate®
11 November 2025
···
1 … 6 7 8 9 10 11

Stock Market Today

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

ST Engineering stock price drops 2% to S$9.71 as drone-autonomy tie-up grabs attention

7 February 2026
ST Engineering shares fell 1.9% to S$9.71 Friday, outpacing the Singapore market’s 0.8% drop amid a tech-led selloff. The company signed a deal with Shield AI at the Singapore Airshow to integrate autonomy software into its unmanned platforms and unveiled a small drone capable of carrying explosives. About 6.9 million shares traded as investors await full-year results on Feb. 27.
Go toTop